KURAKura Oncology, Inc.

KOMZIFTI revenue surged 57% as new patient starts climbed 35%.

Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kura Oncology recently reported past second-quarter 2026 results, with revenue rising to US$20.87 million while net loss widened to US$68.33 million, alongside the publication in Blood of extensive preclinical data on its FDA-approved menin inhibitor ziftomenib (KOMZIFTI) for relapsed or refractory NPM1-mutated AML. The Blood manuscript highlights ziftomenib’s differentiated binding profile, activity across genetically defined leukemia models, and retained activity against certain...

According to a filing with the Securities and Exchange Commission, President and CEO Wilson bought 100,000 shares at an average price of $11.12.

Moby summary of Kura Oncology, Inc.'s Q2 2026 earnings call

Kura Oncology (NASDAQ:KURA) reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that ind

Kura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio (TELA) delivered earnings and revenue surprises of -17.65% and -3.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kura Oncology (NASDAQ:KURA) presented updated results from its Phase 1 FIT-001 trial evaluating darlifarnib in combination with cabozantinib for locally advanced or metastatic renal cell carcinoma (RCC) that had progressed after prior treatment, including immunotherapy. The company’s investor call

Kura Oncology (KURA) is back in focus after announcing that updated Phase 1a data from its FIT-001 trial in advanced renal cell carcinoma will be featured in an oral presentation at the 2026 Kidney Cancer Research Summit. See our latest analysis for Kura Oncology. The FIT-001 update comes after a mixed period for Kura Oncology’s stock, with a 1-month share price return of 9.37% and a 90-day share price return of 11.04% contrasting with a 7-day share price decline of 5.15%. The 1-year total...